Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel vs 5-FU with Cisplatin in ESCC
NCT02969473Phase 2Unknown
- Start
- Oct 2010
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms). Primary endpoint: Overall Survival at 5 years. Status: unknown.
02
Drugs
docetaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02969473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02969473.